Paliperidone Palmitate
FDA-approved product (suspension, extended release, intramuscular), marketed as Erzofri, Invega Hafyera, Invega Sustenna and 1 more.
- Registered studies
- 50+
- Lab records
- 0
- Pathogens at ≥40%
- 4 of 4
Chemical structure
Existing / approved use
Documented · FDA, WHO, ChEMBLApproved for
- Mental or behavioural disorder
- Psychosis
- Schizoaffective disorder
- Schizophrenia
Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗
- WHO therapeutic group
- Other antipsychotics
- Anti-infective classification
- Not classified as an anti-infective.
Repurposing investigation
This medicine is being investigated here for AI-predicted antimicrobial activity against M. tuberculosis, MRSA, E. coli and K. pneumoniae. It was surfaced computationally for further investigation; it is not an established treatment for these infections.
AI-predicted activity
AI prediction · nothing measured- MRSA67.3% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
- E. coli51.4% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
- K. pneumoniae45.2% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
- M. tuberculosis58.0% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.
Evidence
Clinical and experimental
Documented evidenceClinical
50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.
Experimental
No evidence found
No laboratory measurement against the four pathogens in the ChEMBL records loaded here.
Docking
Computational · nothing measuredDihydrofolate reductase ↗ (E. coli)
Not yet docked: queued in the docking rundetails
KPC-2 carbapenemase ↗ (K. pneumoniae)
Not yet docked: queued in the docking rundetails
Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)
Not yet docked: queued in the docking rundetails
Dihydrofolate reductase ↗ (MRSA)
Not yet docked: queued in the docking rundetails
AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.
Other medicines to investigate
AI prediction · nothing measuredOther repurposing candidates: approved medicines besides Paliperidone Palmitate with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.
Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.
- FurazolidoneExisting use: Other antiinfectives and antiseptics91.4% AI-predicted activityagainst M. tuberculosisLab records exist49 registered studies
- TriflupromazineExisting use: Psychosis90.6% AI-predicted activityagainst M. tuberculosisNo documented evidence found
- ValdecoxibExisting use: Dysmenorrhea, Osteoarthritis, Rheumatic disease and 1 more88.6% AI-predicted activityagainst M. tuberculosisLab records exist31 registered studies
- CelecoxibExisting use: Ankylosing spondylitis, Cancer, Colorectal neoplasm and 15 more87.6% AI-predicted activityagainst M. tuberculosisLab records exist50+ registered studies
- Dorzolamide HydrochlorideExisting use: Glaucoma, Ocular hypertension, Open-angle glaucoma86.8% AI-predicted activityagainst M. tuberculosisLab records exist50+ registered studies
- MethazolamideExisting use: Glaucoma, Open-angle glaucoma85.6% AI-predicted activityagainst M. tuberculosisLab records exist11 registered studies
- AcetazolamideExisting use: Altitude sickness, Angle-closure glaucoma, Congestive heart failure and 5 more85.2% AI-predicted activityagainst M. tuberculosisLab records exist50+ registered studies
- Trifluoperazine HydrochlorideExisting use: Anxiety disorder, Mental or behavioural disorder, Psychosis and 1 more84.6% AI-predicted activityagainst M. tuberculosis1 registered study
- TriclosanExisting use: Phenol and derivatives, Medicated dressings with antiinfectives84.2% AI-predicted activityagainst M. tuberculosisLab records exist50+ registered studies
- NitrofurazoneExisting use: Eye infection, Leishmaniasis, Trypanosomiasis84.0% AI-predicted activityagainst M. tuberculosis8 registered studies
- BrinzolamideExisting use: Glaucoma, Ocular hypertension, Open-angle glaucoma83.8% AI-predicted activityagainst M. tuberculosisLab records exist50+ registered studies
- ZonisamideExisting use: Epilepsy, Focal-onset seizure, Partial epilepsy and 1 more82.8% AI-predicted activityagainst M. tuberculosisLab records exist50+ registered studies
Registered studies
A registration describes a study; it does not establish a positive result.
Safety Study With Paliperidone ER Extended-Release (ER) Tablets in Geriatric Patients With Schizophrenia
NCT00085748 · start 2004-08
Registered record
- Registry ID
- NCT00085748
- Conditions
- Schizophrenia
- Interventions
- paliperidone ER
- Study type
- INTERVENTIONAL
- Phase
- Phase 3
- Registry status
- Completed
- Start
- 2004-08
- Completion
- 2005-05
- Enrolment
- 114
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionSchizophreniaInterventionpaliperidone ERPhasePhase 3Registry statusCompletedTrial Evaluating Three Fixed Doses of Paliperidone Extended-Release (ER) Tablets and Olanzapine in the Treatment of Patients With Schizophrenia
NCT00083668 · start 2004-04
Registered record
- Registry ID
- NCT00083668
- Conditions
- Schizophrenia
- Interventions
- Paliperidone ER
- Study type
- INTERVENTIONAL
- Phase
- Phase 3
- Registry status
- Completed
- Start
- 2004-04
- Completion
- 2005-05
- Enrolment
- 619
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionSchizophreniaInterventionPaliperidone ERPhasePhase 3Registry statusCompletedSafety and Efficacy of an Anti-Psychotic in Patients With Schizophrenia
NCT00074477 · start 2003-10
Registered record
- Registry ID
- NCT00074477
- Conditions
- Schizophrenia
- Interventions
- R092670
- Study type
- INTERVENTIONAL
- Phase
- Phase 2
- Registry status
- Completed
- Start
- 2003-10
- Completion
- 2004-07
- Enrolment
- 250
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionSchizophreniaInterventionR092670PhasePhase 2Registry statusCompletedIntramuscular Injections of Paliperidone Palmitate in the Arm or Buttock of Subjects With Schizophrenia
NCT00073320 · start 2003-08
Registered record
- Registry ID
- NCT00073320
- Conditions
- Schizophrenia
- Interventions
- Paliperidone Palmitate
- Study type
- INTERVENTIONAL
- Phase
- Phase 3
- Registry status
- Completed
- Start
- 2003-08
- Completion
- 2004-05
- Enrolment
- 88
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionSchizophreniaInterventionPaliperidone PalmitatePhasePhase 3Registry statusCompletedAs Study of the Pharmacokinetics of Paliperidone Extended-release and Risperidone Immediate-release Formulations
NCT00796185 · start 2003-08
Registered record
- Registry ID
- NCT00796185
- Conditions
- Schizophrenia; Schizoaffective Disorder
- Interventions
- Paliperidone ER
- Study type
- INTERVENTIONAL
- Phase
- Phase 1
- Registry status
- Completed
- Start
- 2003-08
- Completion
- 2004-01
- Enrolment
- 62
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionSchizophrenia; Schizoaffective DisorderInterventionPaliperidone ERPhasePhase 1Registry statusCompleted